A sustained mortality benefit from screening for abdominal aortic aneurysm.

Autor: Kim LG, Scott RAP, Ashton HA, Thompson SG, Multicentre Aneurysm Screening Study Group, Kim, Lois G, P Scott, R Alan, Ashton, Hilary A, Thompson, Simon G
Zdroj: Annals of Internal Medicine; 5/15/2007, Vol. 146 Issue 10, p699-706, 8p
Abstrakt: Background: Longer-term mortality benefit and cost-effectiveness for abdominal aortic aneurysm (AAA) screening are uncertain.Objective: To estimate the benefits, in terms of AAA-related and all-cause mortality, and cost-effectiveness of ultrasonography screening for AAA in a group that was invited to screening compared with a group that was not invited at a mean 7-year follow-up.Design: Randomized trial.Setting: 4 centers in the United Kingdom.Patients: Population-based sample of 67,770 men age 65 to 74 years.Intervention: Patients with an AAA detected at screening had surveillance and were offered surgery after predefined criteria were met.Measurements: Mortality data were obtained after flagging on the national database. Unit costs obtained from large samples were applied to individual event data for the cost analysis.Results: The hazard ratio was 0.53 (95% CI, 0.42 to 0.68) for AAA-related mortality in the group invited for screening. The rupture rate in men with normal results on initial ultrasonography has remained low: 0.54 rupture (CI, 0.25 to 1.02 ruptures) per 10 000 person-years. In terms of all-cause mortality, the observed hazard ratio was 0.96 (CI, 0.93 to 1.00). At the 7-year follow-up, cost-effectiveness was estimated at $19 500 (CI, $12,400 to $39,800) per life-year gained based on AAA-related mortality and $7600 (CI, $3300 to infinity) per life-year gained based on all-cause death. (All values are reported in U.S. dollars [U.K. 1 pound sterling = U.S. $1.58]).Limitation: Inclusion of deaths from aortic aneurysm at an unspecified site, which may include some thoracic aortic aneurysms, may have underestimated the treatment effect.Conclusions: These results from a large, pragmatic randomized trial show that the early mortality benefit of screening ultrasonography for AAA is maintained in the longer term and that the cost-effectiveness of screening improves over time. International Standard Randomized Controlled Trial registration number: ISRCTN37381646. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index